Agilent Technologies Inc (NYSE:A) Receives Consensus Rating of “Buy” from Analysts

Agilent Technologies Inc (NYSE:A) has earned a consensus recommendation of “Buy” from the seventeen brokerages that are presently covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $84.77.

Several equities analysts have recently issued reports on the company. Deutsche Bank decreased their target price on Agilent Technologies from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Wednesday, May 15th. ValuEngine lowered Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Friday, July 12th. Robert W. Baird restated an “outperform” rating and set a $82.00 target price (up from $79.00) on shares of Agilent Technologies in a research report on Thursday, August 15th. Wolfe Research assumed coverage on Agilent Technologies in a research report on Thursday, May 30th. They set a “peer perform” rating for the company. Finally, Zacks Investment Research lowered Agilent Technologies from a “buy” rating to a “hold” rating and set a $75.00 target price for the company. in a research report on Monday, August 19th.

NYSE:A traded up $0.76 on Friday, hitting $74.28. 3,097,900 shares of the stock were exchanged, compared to its average volume of 2,324,541. The stock has a market capitalization of $22.75 billion, a price-to-earnings ratio of 26.62, a P/E/G ratio of 1.96 and a beta of 1.40. Agilent Technologies has a 52 week low of $61.01 and a 52 week high of $82.27. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.72 and a current ratio of 2.13. The company’s 50-day moving average price is $69.71 and its 200 day moving average price is $74.05.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, August 14th. The medical research company reported $0.76 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.72 by $0.04. The firm had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.24 billion. Agilent Technologies had a return on equity of 20.00% and a net margin of 21.06%. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.67 EPS. As a group, equities research analysts predict that Agilent Technologies will post 3.08 earnings per share for the current year.

In related news, Director Heidi Fields sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $70.96, for a total value of $283,840.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Edgestream Partners L.P. bought a new stake in Agilent Technologies in the 2nd quarter valued at approximately $2,616,000. Stratos Wealth Partners LTD. lifted its stake in Agilent Technologies by 2.7% in the 1st quarter. Stratos Wealth Partners LTD. now owns 31,792 shares of the medical research company’s stock valued at $2,555,000 after acquiring an additional 850 shares in the last quarter. Prentiss Smith & Co. Inc. lifted its stake in Agilent Technologies by 484.9% in the 2nd quarter. Prentiss Smith & Co. Inc. now owns 58,428 shares of the medical research company’s stock valued at $4,363,000 after acquiring an additional 48,438 shares in the last quarter. TimesSquare Capital Management LLC lifted its stake in Agilent Technologies by 0.7% in the 1st quarter. TimesSquare Capital Management LLC now owns 1,007,700 shares of the medical research company’s stock valued at $80,999,000 after acquiring an additional 7,200 shares in the last quarter. Finally, Nordea Investment Management AB lifted its stake in Agilent Technologies by 510.5% in the 1st quarter. Nordea Investment Management AB now owns 112,292 shares of the medical research company’s stock valued at $9,028,000 after acquiring an additional 93,898 shares in the last quarter.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

See Also: What Does a Sell-Side Analyst Rating Mean?

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.